$PRME
Prime Medicine, Inc. Stock $prme

$prme Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024008116 Filed on March 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$591.0K	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.16M	$13.08M	$43.39M
YoY Change	21.91%	35.94%	45.5%
% of Gross Profit
Research & Development	$37.77M	$41.46M	$147.9M
YoY Change	22.33%	42.66%	70.54%
% of Gross Profit
Depreciation & Amortization	$1.315M	$1.247M	$4.653M
YoY Change	25.0%	43.33%	111.5%
% of Gross Profit
Operating Expenses	$48.93M	$68.04M	$204.8M
YoY Change	22.23%	75.89%	75.72%
Operating Profit	-$48.34M		-$204.8M
YoY Change	20.75%		75.72%
Interest Expense	$1.166M	$635.0K	-$2.382M
YoY Change	-168.55%	-137.16%	-70.69%
% of Operating Profit
Other Income/Expense, Net	$2.714M	$1.765M	$6.380M
YoY Change	525.35%	90.6%	-202.49%
Pretax Income	-$45.63M	-$65.64M	-$198.4M
YoY Change	15.22%	66.32%	61.61%
Income Tax	$134.0K	$0.00	-$279.0K
% Of Pretax Income
Net Earnings	-$45.76M	-$65.64M	-$198.1M
YoY Change	16.15%	61.69%	62.64%
Net Earnings / Revenue	-7742.98%
Basic Earnings Per Share	-$0.44		-$2.18
Diluted Earnings Per Share	-$0.44	-$0.71	-$2.18
COMMON SHARES
Basic Shares Outstanding	119.9M shares	97.32M shares	90.97M shares
Diluted Shares Outstanding	104.5M shares		90.97M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$210.7M	$121.7M	$121.7M
YoY Change	-13.42%	-57.47%	-58.61%
Cash & Equivalents	$94.16M	$41.57M	$41.57M
Short-Term Investments	$116.6M	$80.09M	$80.09M
Other Short-Term Assets	$2.728M	$2.254M	$21.31M
YoY Change	-31.49%	-16.43%	690.17%
Inventory
Prepaid Expenses	$4.203M	$19.06M
Receivables
Other Receivables
Total Short-Term Assets	$217.7M	$143.0M	$143.0M
YoY Change	-14.14%	-51.8%	-51.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.93M	$22.66M	$36.60M
YoY Change	10.82%	19.2%	-24.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$779.0K	$779.0K	$14.28M
YoY Change	-52.67%	-52.67%	-5.73%
Total Long-Term Assets	$93.73M	$50.88M	$50.88M
YoY Change	47.73%	-20.13%	-20.13%
TOTAL ASSETS
Total Short-Term Assets	$217.7M	$143.0M	$143.0M
Total Long-Term Assets	$93.73M	$50.88M	$50.88M
Total Assets	$311.4M	$193.9M	$193.9M
YoY Change	-1.76%	-46.2%	-46.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.08M	$19.54M	$19.54M
YoY Change	120.96%	350.99%	350.99%
Accrued Expenses	$7.612M	$14.11M	$33.32M
YoY Change	0.91%	32.02%	63.45%
Deferred Revenue		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.44M	$56.42M	$56.42M
YoY Change	2.39%	111.21%	111.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$43.04M	$4.357M	$4.357M
YoY Change	203.18%	-74.45%	-74.45%
Total Long-Term Liabilities	$43.04M	$4.357M	$4.357M
YoY Change	203.18%	-74.45%	-74.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.44M	$56.42M	$56.42M
Total Long-Term Liabilities	$43.04M	$4.357M	$4.357M
Total Liabilities	$67.62M	$60.78M	$60.78M
YoY Change	77.26%	38.0%	38.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$537.1M	-$491.3M
YoY Change	61.49%	67.56%
Common Stock	$2.000K	$2.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$243.8M	$133.1M	$133.1M
YoY Change
Total Liabilities & Shareholders Equity	$311.4M	$193.9M	$193.9M
YoY Change	-1.76%	-46.2%	-46.2%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$45.76M	-$65.64M	-$198.1M
YoY Change	16.15%	61.69%	62.64%
Depreciation, Depletion And Amortization	$1.315M	$1.247M	$4.653M
YoY Change	25.0%	43.33%	111.5%
Cash From Operating Activities	-$67.71M	-$43.86M	-$165.4M
YoY Change	62.91%	42.82%	25.48%
INVESTING ACTIVITIES
Capital Expenditures	$2.324M	$1.840M	$8.724M
YoY Change	16.26%	-61.78%	-45.8%
Acquisitions
YoY Change
Other Investing Activities	-$34.71M	$43.13M	$27.44M
YoY Change	225.41%	-586.03%	-188.5%
Cash From Investing Activities	-$37.03M	$41.29M	$18.71M
YoY Change	192.4%	-401.64%	-139.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$157.3M	194.0K	$655.0K
YoY Change	231263.24%	-99.89%	-99.64%
NET CHANGE
Cash From Operating Activities	-$67.71M	-43.86M	-$165.4M
Cash From Investing Activities	-$37.03M	41.29M	$18.71M
Cash From Financing Activities	$157.3M	194.0K	$655.0K
Net Change In Cash	$52.59M	-2.385M	-$146.0M
YoY Change	-197.1%	-101.71%	-5780.51%
FREE CASH FLOW
Cash From Operating Activities	-$67.71M	-$43.86M	-$165.4M
Capital Expenditures	$2.324M	$1.840M	$8.724M
Free Cash Flow	-$70.03M	-$45.70M	-$174.1M
YoY Change	60.77%	28.65%	17.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6380000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6225000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-198412000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22659000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19009000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29545000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	779000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1646000	usd
CY2023Q4	us-gaap	Assets Assets	193851000	usd
CY2022Q4	us-gaap	Assets Assets	360314000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19537000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4332000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14110000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001894562
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.32167
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41536
CY2023	dei	Entity Registrant Name EntityRegistrantName	PRIME MEDICINE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3097762
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Erie Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2023	dei	City Area Code CityAreaCode	(617)
CY2023	dei	Local Phone Number LocalPhoneNumber	564-0013
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.00001 per share
CY2023	dei	Trading Symbol TradingSymbol	PRME
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	603127652	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	119939247	shares
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41574000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187620000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	19057000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2451000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2254000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	246000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	142976000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	296618000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22659000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19009000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13941000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29545000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	779000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1646000	usd
CY2023Q4	us-gaap	Assets Assets	193851000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19537000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14110000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10688000	usd
CY2023Q4	prme	Accrued Settlement Payment Current AccruedSettlementPaymentCurrent	13500000	usd
CY2022Q4	prme	Accrued Settlement Payment Current AccruedSettlementPaymentCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9276000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11694000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	56423000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26714000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4357000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17051000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	279000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	60780000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	44044000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97377121	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97209213	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97209213	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	624414000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	609849000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-384000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10688000	usd
CY2023Q4	prme	Accrued Settlement Payment Current AccruedSettlementPaymentCurrent	13500000	usd
CY2022Q4	prme	Accrued Settlement Payment Current AccruedSettlementPaymentCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9276000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11694000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	56423000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26714000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4357000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17051000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	279000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	60780000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	44044000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97377121	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97377121	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97209213	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97209213	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	624414000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	609849000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-384000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-491330000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293197000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	133071000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316270000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	193851000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	360314000	usd
CY2023	prme	Settlement Payment Expense SettlementPaymentExpense	13500000	usd
CY2022	prme	Settlement Payment Expense SettlementPaymentExpense	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	204792000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-204792000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-116544000	usd
CY2023	prme	Change In Fair Value Of Short Term Investment ChangeInFairValueOfShortTermInvestment	-2382000	usd
CY2022	prme	Change In Fair Value Of Short Term Investment ChangeInFairValueOfShortTermInvestment	-8128000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8762000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1903000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-122769000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-948000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-491330000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293197000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	133071000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316270000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	193851000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	360314000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	147905000	usd
CY2023	prme	Settlement Payment Expense SettlementPaymentExpense	13500000	usd
CY2022	prme	Settlement Payment Expense SettlementPaymentExpense	0	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43387000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	204792000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	116544000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-204792000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-116544000	usd
CY2023	prme	Change In Fair Value Of Short Term Investment ChangeInFairValueOfShortTermInvestment	-2382000	usd
CY2022	prme	Change In Fair Value Of Short Term Investment ChangeInFairValueOfShortTermInvestment	-8128000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8762000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1903000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-948000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	20193000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-198133000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-198133000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142014000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142014000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.18
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.18
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.19
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.19
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90969327	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90969327	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33891264	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33891264	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	369000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-357000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-197764000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-122178000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-156240000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	219000	usd
CY2022	prme	Additional Paid In Capital Reclassification Of Forward Contract Value AdditionalPaidInCapitalReclassificationOfForwardContractValue	12020000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	395801000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	180189000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6459000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-357000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316270000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	20193000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-198133000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-198133000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142014000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142014000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.18
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.18
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.19
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.19
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90969327	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90969327	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33891264	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33891264	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	369000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-357000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-197764000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-122178000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-156240000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	219000	usd
CY2022	prme	Additional Paid In Capital Reclassification Of Forward Contract Value AdditionalPaidInCapitalReclassificationOfForwardContractValue	12020000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	395801000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	180189000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6459000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-357000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316270000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	655000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	13910000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	369000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	133071000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	13910000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6459000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	12788000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	9790000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4653000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2224000	usd
CY2023	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-2382000	usd
CY2022	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-8128000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-28000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3408000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	250000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-964000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9455000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1738000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	655000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	13910000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	369000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	133071000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	13910000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6459000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	12788000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	9790000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4653000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2224000	usd
CY2023	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-2382000	usd
CY2022	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-8128000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-28000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3408000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	250000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-964000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9455000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1738000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9140000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2458000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1758000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-25873000	usd
CY2023	prme	Increase Decrease In Accrued Settlement Payment IncreaseDecreaseInAccruedSettlementPayment	13500000	usd
CY2022	prme	Increase Decrease In Accrued Settlement Payment IncreaseDecreaseInAccruedSettlementPayment	0	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12296000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-10248000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-165412000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-131827000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	132556000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	93000000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	104951000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	123336000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8724000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16095000	usd
CY2023	prme	Payments For Security Deposits PaymentsForSecurityDeposits	170000	usd
CY2022	prme	Payments For Security Deposits PaymentsForSecurityDeposits	665000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18711000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47096000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	655000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	219000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	185317000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4042000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	655000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	181494000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-146046000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2571000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9140000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1758000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-25873000	usd
CY2023	prme	Increase Decrease In Accrued Settlement Payment IncreaseDecreaseInAccruedSettlementPayment	13500000	usd
CY2022	prme	Increase Decrease In Accrued Settlement Payment IncreaseDecreaseInAccruedSettlementPayment	0	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12296000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-10248000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-165412000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-131827000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	132556000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	93000000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	104951000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	123336000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8724000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16095000	usd
CY2023	prme	Payments For Security Deposits PaymentsForSecurityDeposits	170000	usd
CY2022	prme	Payments For Security Deposits PaymentsForSecurityDeposits	665000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18711000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47096000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	655000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	219000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	185317000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4042000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	655000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	181494000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2571000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198545000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55070000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55070000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41574000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187620000	usd
CY2023	prme	Decrease In Right Of Use Asset Due To Lease Termination DecreaseInRightOfUseAssetDueToLeaseTermination	6081000	usd
CY2022	prme	Decrease In Right Of Use Asset Due To Lease Termination DecreaseInRightOfUseAssetDueToLeaseTermination	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3265000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28590000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	575000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	969000	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	395800000	usd
CY2023	prme	Settlement Of Related Party Forward Contract SettlementOfRelatedPartyForwardContract	0	usd
CY2022	prme	Settlement Of Related Party Forward Contract SettlementOfRelatedPartyForwardContract	12020000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	141000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-491300000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	121700000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198545000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55070000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55070000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41574000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187620000	usd
CY2023	prme	Decrease In Right Of Use Asset Due To Lease Termination DecreaseInRightOfUseAssetDueToLeaseTermination	6081000	usd
CY2022	prme	Decrease In Right Of Use Asset Due To Lease Termination DecreaseInRightOfUseAssetDueToLeaseTermination	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3265000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28590000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	575000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	969000	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	395800000	usd
CY2023	prme	Settlement Of Related Party Forward Contract SettlementOfRelatedPartyForwardContract	0	usd
CY2022	prme	Settlement Of Related Party Forward Contract SettlementOfRelatedPartyForwardContract	12020000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	141000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-491300000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	121700000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ materially from those estimates or assumptions. Significant estimates, as determined by the Company, are discussed in greater detail in Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5452000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	104300000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ materially from those estimates or assumptions. Significant estimates, as determined by the Company, are discussed in greater detail in Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, and restricted cash. The Company invests in U.S. Treasury securities and maintains its cash and cash equivalents at high-quality and accredited financial institutions in amounts that could exceed federally insured limits. Cash equivalents are invested in money market funds. However, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div>
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	7834000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, and restricted cash. The Company invests in U.S. Treasury securities and maintains its cash and cash equivalents at high-quality and accredited financial institutions in amounts that could exceed federally insured limits. Cash equivalents are invested in money market funds. However, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div>
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5452000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	104300000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	7834000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	226812000	usd
CY2023Q4	prme	Debt And Equity Securities Amortized Cost DebtAndEquitySecuritiesAmortizedCost	74654000	usd
CY2023Q4	prme	Debt And Equity Securities Unrealized Gains DebtAndEquitySecuritiesUnrealizedGains	7000	usd
CY2023Q4	prme	Debt And Equity Securities Unrealized Loss DebtAndEquitySecuritiesUnrealizedLoss	22000	usd
CY2023Q4	prme	Debt And Equity Securities DebtAndEquitySecurities	74639000	usd
CY2022Q4	prme	Debt And Equity Securities Amortized Cost DebtAndEquitySecuritiesAmortizedCost	98851000	usd
CY2022Q4	prme	Debt And Equity Securities Unrealized Gains DebtAndEquitySecuritiesUnrealizedGains	0	usd
CY2022Q4	prme	Debt And Equity Securities Unrealized Loss DebtAndEquitySecuritiesUnrealizedLoss	384000	usd
CY2022Q4	prme	Debt And Equity Securities DebtAndEquitySecurities	98467000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	74639000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	98467000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30143000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21840000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7484000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2831000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22659000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4653000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2224000	usd
CY2023Q4	prme	Debt And Equity Securities Amortized Cost DebtAndEquitySecuritiesAmortizedCost	74654000	usd
CY2023Q4	prme	Debt And Equity Securities Unrealized Gains DebtAndEquitySecuritiesUnrealizedGains	7000	usd
CY2023Q4	prme	Debt And Equity Securities Unrealized Loss DebtAndEquitySecuritiesUnrealizedLoss	22000	usd
CY2022Q4	prme	Debt And Equity Securities Amortized Cost DebtAndEquitySecuritiesAmortizedCost	98851000	usd
CY2022Q4	prme	Debt And Equity Securities Unrealized Gains DebtAndEquitySecuritiesUnrealizedGains	0	usd
CY2022Q4	prme	Debt And Equity Securities Unrealized Loss DebtAndEquitySecuritiesUnrealizedLoss	384000	usd
CY2022Q4	prme	Debt And Equity Securities DebtAndEquitySecurities	98467000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	74639000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	98467000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30143000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21840000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7484000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2831000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22659000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19009000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4653000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2224000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8270000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6529000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2273000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2162000	usd
CY2023Q4	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	1962000	usd
CY2022Q4	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	1219000	usd
CY2023Q4	prme	Accrued Research And Development Expense Related Party AccruedResearchAndDevelopmentExpenseRelatedParty	0	usd
CY2022Q4	prme	Accrued Research And Development Expense Related Party AccruedResearchAndDevelopmentExpenseRelatedParty	329000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1605000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	449000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14110000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10688000	usd
CY2023Q4	prme	Common Stock Par Or Stated Value Per Share Under Amendment CommonStockParOrStatedValuePerShareUnderAmendment	0.0001
CY2023Q4	prme	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8270000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6529000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2273000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2162000	usd
CY2023Q4	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	1962000	usd
CY2022Q4	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	1219000	usd
CY2023Q4	prme	Accrued Research And Development Expense Related Party AccruedResearchAndDevelopmentExpenseRelatedParty	0	usd
CY2022Q4	prme	Accrued Research And Development Expense Related Party AccruedResearchAndDevelopmentExpenseRelatedParty	329000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1605000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	449000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14110000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10688000	usd
CY2023Q4	prme	Common Stock Par Or Stated Value Per Share Under Amendment CommonStockParOrStatedValuePerShareUnderAmendment	0.0001
CY2023Q4	prme	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13910000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6459000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	16000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-314000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-650000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-964000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-948000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13910000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6459000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	16000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-314000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-650000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-964000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-279000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-948000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.073
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.020
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.029
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.009
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.289
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.300
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.007
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	49990000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	19974000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35977000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20427000	usd
CY2023Q4	prme	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	13204000	usd
CY2022Q4	prme	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	13307000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	12863000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7268000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5817000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1649000	usd
CY2023Q4	prme	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	3711000	usd
CY2022Q4	prme	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	7853000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1473000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	122000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	9000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	123044000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70600000	usd
CY2023Q4	prme	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	3794000	usd
CY2022Q4	prme	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	8072000	usd
CY2023Q4	prme	Deferred Tax Liabilities Adjustments DeferredTaxLiabilitiesAdjustments	0	usd
CY2022Q4	prme	Deferred Tax Liabilities Adjustments DeferredTaxLiabilitiesAdjustments	675000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3794000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8747000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	119250000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62132000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	279000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.073
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.020
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.029
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.009
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.289
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.300
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.007
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	49990000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	19974000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35977000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20427000	usd
CY2023Q4	prme	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	13204000	usd
CY2022Q4	prme	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	13307000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	12863000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7268000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5817000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1649000	usd
CY2023Q4	prme	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	3711000	usd
CY2022Q4	prme	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	7853000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1473000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	122000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	9000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	123044000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70600000	usd
CY2023Q4	prme	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	3794000	usd
CY2022Q4	prme	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	8072000	usd
CY2023Q4	prme	Deferred Tax Liabilities Adjustments DeferredTaxLiabilitiesAdjustments	0	usd
CY2022Q4	prme	Deferred Tax Liabilities Adjustments DeferredTaxLiabilitiesAdjustments	675000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3794000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8747000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	119250000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62132000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	279000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	131608000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	75202000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	132009000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	73339000	usd
CY2023	prme	Research And Development Costs Capitalized ResearchAndDevelopmentCostsCapitalized	137200000	usd
CY2022	prme	Research And Development Costs Capitalized ResearchAndDevelopmentCostsCapitalized	80700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62132000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25253000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	57118000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36879000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	119250000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62132000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	prme	Lessee Operating Lease Termination Notice Period LesseeOperatingLeaseTerminationNoticePeriod	P7M
CY2023Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	6100000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	13664000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	10999000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	2145000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1111000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2816000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1401000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	168000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	294000	usd
CY2023	us-gaap	Lease Cost LeaseCost	18457000	usd
CY2022	us-gaap	Lease Cost LeaseCost	13217000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	131608000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	75202000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	132009000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	73339000	usd
CY2023	prme	Research And Development Costs Capitalized ResearchAndDevelopmentCostsCapitalized	137200000	usd
CY2022	prme	Research And Development Costs Capitalized ResearchAndDevelopmentCostsCapitalized	80700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62132000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25253000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	57118000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36879000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	119250000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62132000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	prme	Lessee Operating Lease Termination Notice Period LesseeOperatingLeaseTerminationNoticePeriod	P7M
CY2023Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	6100000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	13664000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	10999000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	2145000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1111000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1401000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	168000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	294000	usd
CY2023	us-gaap	Lease Cost LeaseCost	18457000	usd
CY2022	us-gaap	Lease Cost LeaseCost	13217000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0692
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0492
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9669000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2656000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1683000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	567000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14575000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	942000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13633000	usd
CY2023Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	43500000	usd
CY2023	prme	Settlement Payment Expense SettlementPaymentExpense	13500000	usd
CY2023	prme	Settlement Payment Expense SettlementPaymentExpense	13500000	usd
CY2023	prme	Settlement Payment Expense SettlementPaymentExpense	13500000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12499019	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13213798	shares
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0692
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0492
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9669000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2656000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1683000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	567000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14575000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	942000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13633000	usd
CY2023Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	43500000	usd
CY2023	prme	Settlement Payment Expense SettlementPaymentExpense	13500000	usd
CY2023	prme	Settlement Payment Expense SettlementPaymentExpense	13500000	usd
CY2023	prme	Settlement Payment Expense SettlementPaymentExpense	13500000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12499019	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13213798	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	20193000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-198133000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-198133000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142014000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142014000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90969327	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90969327	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33891264	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33891264	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.18
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.18
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.19
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.19
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-198133000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	20193000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-198133000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-198133000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142014000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142014000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90969327	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90969327	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33891264	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33891264	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.18
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.18
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.19
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.19
CY2023	prme	Settlement Payment Expense SettlementPaymentExpense	13500000	usd

Files In Submission

Name	View Source	Status
prme-20231231_cal.xml	Edgar Link	unprocessable
0001628280-24-008116-index-headers.html	Edgar Link	pending
0001628280-24-008116-index.html	Edgar Link	pending
0001628280-24-008116.txt	Edgar Link	pending
0001628280-24-008116-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fy2023ex1022-mil21e12thame.htm	Edgar Link	pending
fy2023ex231-pwcconsent.htm	Edgar Link	pending
fy2023ex311-ceo302certific.htm	Edgar Link	pending
fy2023ex312-cfo302certific.htm	Edgar Link	pending
fy2023ex321-ceo906certific.htm	Edgar Link	pending
fy2023ex322-cfo906certific.htm	Edgar Link	pending
fy2023ex43-descriptionofse.htm	Edgar Link	pending
fy2023ex971-comprecoverypo.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prme-20231231.htm	Edgar Link	pending
prme-20231231.xsd	Edgar Link	pending
prme-20231231_g1.jpg	Edgar Link	pending
prme-20231231_g10.gif	Edgar Link	pending
prme-20231231_g11.gif	Edgar Link	pending
prme-20231231_g12.gif	Edgar Link	pending
prme-20231231_g13.gif	Edgar Link	pending
prme-20231231_g14.gif	Edgar Link	pending
prme-20231231_g15.gif	Edgar Link	pending
prme-20231231_g16.gif	Edgar Link	pending
prme-20231231_g17.gif	Edgar Link	pending
prme-20231231_g18.gif	Edgar Link	pending
prme-20231231_g19.gif	Edgar Link	pending
prme-20231231_g2.jpg	Edgar Link	pending
prme-20231231_g20.gif	Edgar Link	pending
prme-20231231_g21.gif	Edgar Link	pending
prme-20231231_g22.gif	Edgar Link	pending
prme-20231231_g23.gif	Edgar Link	pending
prme-20231231_g24.gif	Edgar Link	pending
prme-20231231_g3.jpg	Edgar Link	pending
prme-20231231_g4.jpg	Edgar Link	pending
prme-20231231_g5.gif	Edgar Link	pending
prme-20231231_g6.gif	Edgar Link	pending
prme-20231231_g7.gif	Edgar Link	pending
prme-20231231_g8.gif	Edgar Link	pending
prme-20231231_g9.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
prme-20231231_lab.xml	Edgar Link	unprocessable
prme-20231231_pre.xml	Edgar Link	unprocessable
prme-20231231_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
prme-20231231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRME
Prime Medicine, Inc. Stock $prme

2024 Q1 Form 10-K Financial Statement

#000162828024008116 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME Prime Medicine, Inc. Stock $prme

2024 Q1 Form 10-K Financial Statement

#000162828024008116 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME
Prime Medicine, Inc. Stock $prme